Ignite Creation Date:
2024-05-06 @ 3:25 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04624113
Status:
TERMINATED
Last Update Posted:
2024-02-21
First Post:
2020-11-09
Brief Title:
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Sponsor:
Organization:
Washington University School of Medicine